TY - JOUR
T1 - Rubella
AU - Lambert, Nathaniel
AU - Strebel, Peter
AU - Orenstein, Walter
AU - Icenogle, Joseph
AU - Poland, Gregory A.
N1 - Funding Information:
Research reported in this Seminar was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R37AI48793 (which recently received a MERIT Award). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The findings and conclusions in this Seminar are those of the authors and do not necessarily represent the views of the US Department of Health and Human Services. PS is a staff member of the World Health Organization. PS is responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of the World Health Organization. We thank Caroline L Vitse for her editorial assistance.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/6/6
Y1 - 2015/6/6
N2 - Rubella remains an important pathogen worldwide, with roughly 100 000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome.
AB - Rubella remains an important pathogen worldwide, with roughly 100 000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome.
UR - http://www.scopus.com/inward/record.url?scp=84934296933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84934296933&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(14)60539-0
DO - 10.1016/S0140-6736(14)60539-0
M3 - Article
C2 - 25576992
AN - SCOPUS:84934296933
VL - 385
SP - 2297
EP - 2307
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9984
ER -